Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.69 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22158299 | 0.83 | ROCK2 (0.75) | MAOBROCK2ROCK1RPS6KB1TP53 | |
| SCHEMBL1986301 | 0.78 | ROCK2 (0.67) | MAOBROCK2ROCK1HDAC1HDAC2 | |
| SCHEMBL12562026 | 0.75 | MAOB (0.68) | MAOBROCK2RPS6KB1HDAC1HDAC2 | |
| SCHEMBL28637459 | 0.74 | ROCK2 (0.65) | MAOBROCK2RPS6KB1HDAC1HDAC2 | |
| SCHEMBL1990908 | 0.74 | ROCK2 (1.00) | ROCK2ROCK1RPS6KB1 | |
| SCHEMBL17737363 | 0.74 | MAOB (0.52) | MAOBROCK2ROCK1RPS6KB1HDAC1 | |
| SCHEMBL22158349 | 0.72 | ROCK2 (0.58) | MAOBROCK2RPS6KB1HDAC1HDAC2 | |
| SCHEMBL22158319 | 0.72 | MAOB (0.68) | MAOBROCK2ROCK1RPS6KB1ADORA2A | |
| SCHEMBL22165399 | 0.72 | MAOB (0.68) | MAOBROCK2RPS6KB1TP53 | |
| SCHEMBL30292017 | 0.72 | MAOB (0.68) | MAOBROCK2RPS6KB1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617214-B2 | Compounds for cognitive enhancement and methods of use thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617214-B2 | Compounds for cognitive enhancement and methods of use thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015070170-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | ROCK1, ROCK2, RHOA | MAOB 267/4885ROCK2 2/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.